Skip to main content
. Author manuscript; available in PMC: 2015 Jul 30.
Published in final edited form as: Cell. 2014 Dec 18;159(7):1549–1562. doi: 10.1016/j.cell.2014.11.036

Figure 2. Loss of Caspase-9 Results in Elevated Type I Interferon In Vivo.

Figure 2

(A) FACS analysis of mixed bone marrow chimeras 12–16 weeks posttransplant of WT (CD45.2+) or Casp9−/− (CD45.2+) with WT “bystander” (CD45.1 +CD45.2+) E13.5 FLCs into lethally irradiated CD45.1+ recipients. Number of donor-derived bone marrow LSK cells from both fractions is displayed (n = 8 mixed bone marrow chimeras per genotype from 3–4 fetal livers per genotype). Means of WT (CD45.1 +CD45.2+) “bystander” cells were compared using a two-tailed t test.

(B) Sca1 expression on Lin−Kit+ bone marrow cells from mixed bone marrow chimeras.

(C) Scatterplot of differentially expressed probes in microarray analysis of WT, Casp9−/−, and Bak−/− Bax−/− Lin−Kit+CD45.2+ bone marrow cells. See also Table S1.

(D) Top ten gene sets (ranked by p value) from Gene Set Enrichment Analysis (GSEA) of Casp9−/− in (C) (gray indicates type I IFN signatures).

(E) Top ten gene sets (ranked by p value) from GSEA of Bak−/− Bax−/− in (C).

(F and G) Real-time qPCR analysis of type I ISGs in fetal liver (F) and bone marrow cells (G) (n = 3–4 E13.5 fetal livers and 3–4 bone marrow chimeras per genotype). (H) IFN-β protein in serum of WT (n = 6), Casp9−/− (n = 6), and Bak−/− Bax−/− (n = 8) bone marrow chimeras.

Unless indicated, means were compared to WT using a one-way ANOVA with Bonferroni correction. Data represent the mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.005.